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Abstract. Head and neck cancer (HNC) is the leading cancer 
in Sri Lankan males and second most common cancer among 
Sri Lankan females. This is the first study, to the best of our 
knowledge, that has focused on investigating the associa-
tion between TP53 somatic DNA variants, with p53 protein 
expression and risk factors in a cohort of Sri Lankan patients 
with HNC. A total of 44 patients with cancer and 20 healthy 
controls were studied. In total, 36 genomic DNA sequence 
variants were found, including several novel variants (two 
deletions in exons 4 and 6, two in the 3' untranslated region 
and several intronic variants). A total of 14 tumour samples 
carried pathogenic TP53 mutations. A random selection of 
24 samples was analysed immunohistochemically for p53 
protein expression. All the samples with point missense vari-
ants were strongly immuno‑positive, whereas, samples with 
nonsense and frameshift TP53 variants were immuno‑negative 
for p53 immunohistochemical staining. Although, the human 
papilloma virus is a known risk factor for HNC, results from 
the present study identified an absence or lower level of infec-
tion in the Sri Lankan cohort.
Introduction
Head and neck cancer (HNC) is a broad spectrum of disease 
that encompasses malignancies in the aero‑digestive tract, 
including the oral cavity, pharynx, larynx, nasal cavity, 
paranasal sinuses, salivary glands, thyroid and parathyroid 
glands (1). HNC is the sixth most common cancer worldwide. 
Sri Lanka is considered as one of the high‑risk countries, 
where HNCs are the leading cancer type in men accounting 
for 29% of all cancers (2-4).
Cigarette smoking and alcohol consumption, which are 
considered to be the most common risk factors for HNC, are 
generally lower in Sri Lankans compared to Western popula-
tions (2,5). However, tobacco chewing and consumption of 
areca nut are considered to be the most common causes of 
HNC in Sri Lankan males (3,5‑7). Tobacco chewing results in 
exposure to 28 known carcinogens, including the non‑volatile 
alkaloid‑derived tobacco‑specific N‑nitrosamine and 
N-nitrosamino acids, which are different from the carcinogens 
involved in smoking cigarettes (3,8). The high risk associated 
with human papilloma virus (HPV) infection for specific 
types of HNCs is well established and studied in different 
geographical areas (9). However there is a scarcity of literature 
available on HPV associated HNC in the Sri Lankan popula-
tion.
p53 acts as a ‘guardian of the genome’ to maintain the 
balance of cell death and proliferation by regulating the cell 
cycle, DNA repair, apoptosis, cellular metabolism and senes-
cence (10). It is altered in ~50% of cancers overall and is more 
frequent in adult vs. childhood malignancies (11). The efficacy 
of many cancer therapeutic approaches is influenced by the 
functional status of the p53 tumour suppressor protein. Thus 
identification of TP53 mutation status prior to administration 
of therapy can predict potential effectiveness of the treatment 
and influence treatment selection. Furthermore, the TP53 
mutation spectrum provides information on tumour origin, 
cause of mutation, aetiology, molecular pathogenesis, predic-
tion of patient survival and chances of recurrence (12‑15).
There were numerous studies on TP53 variants in various 
cancers including head and neck cancer over the last few 
decades, particularly in Western populations. But there 
are only few studies done considering all subsets of HNC 
in Asia including India (16) and Japan (17) excluding Sri 
Lanka. Since the frequency of TP53 mutations and the muta-
tion spectra vary in different geographic areas, according to 
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aetiological factors, life style, dietary pattern and culture, the 
present study has focused on establishing the TP53 mutation 
spectrum in Sri Lankan HNC patients. Furthermore we used 
immunohistochemistry (IHC) to assess p53 protein expression 
and correlated immuno‑expression of p53 with TP53 gene 
mutational status. We also studied HPV infection in HNC and 
oesophageal cancer using p16 immuno‑expression and HPV 
DNA detection, as the latter has reported to be associated with 
oral cancer in Sri Lankan patients (18).
Materials and methods
Patient recruitment and sample processing. Ethical approval 
was obtained from the Ethics Review Committee, Faculty 
of Medicine, University of Colombo, Sri Lanka (EC/14/160). 
Patients with HNC (N=44) who had undergone surgical resec-
tion at the National Cancer Institute, Sri Lanka, were recruited 
for this study. Written informed consent from the study partic-
ipants was obtained prior to recruitment. Socio‑demographic 
and clinical data were obtained from study participants using 
questionnaires and by reviewing their medical reports. The 
majority of our patient population represents the Sinhalese 
ethnicity. Healthy controls (N=20; 10 males, 10 females) with 
no personal/family history of any cancer were recruited for 
this study.
Surgically excised tumour tissues were collected and the 
close adjacent region of the tissue section was placed in 10% 
formalin to prepare Formalin Fixed Paraffin Embedded tissue 
while the other section was immediately placed in Allprotect® 
Tissue Reagent (cat no. 76405; Qiagen, Hilden, Germany) and 
stored at ‑20˚C until processed. The hematoxylin and eosin 
stained slides of each tissue were reviewed by a pathologist 
to confirm the percentage of tumour region. Studied samples 
were with >50% area coverage of tumour in the study, except 
only two samples had <10% of tumour cells in the sections.
Genomic DNA was extracted from the excised tumour 
tissue of patients and from peripheral venous blood of healthy 
controls. Disruption of tissue specimens was done in liquid 
nitrogen using a motor and pestle followed by homogeniza-
tion using QIAshredder (cat. no. 79654; Qiagen). Tissue DNA 
was extracted from homogenized sample using an All prep 
DNA/RNA/Protein mini kit (cat. no. 80004; Qiagen) following 
the manufacturer's protocol and stored at ‑20˚C until used. 
Genomic DNA was extracted from blood using the modified 
protocol described by Miller et al (19).
Seven sets of primers covering the entire exon 2‑11 coding 
regions and adjacent flanking 5' and 3' intronic regions 
were designed using the online NCBI/Primer‑BLAST soft-
ware (https://www.ncbi.nlm.nih.gov/tools/primerblast/index.
cgi?ORGANISM=9606&INPUT_SEQUENCE=NM_001618.3). 
Polymerase Chain Reaction (PCR) amplification was 
performed using each primer set in a final volume of 25 µl 
containing 100 ng genomic DNA, 3.5 mM MgCl2, 1X Green 
GoTaq® reaction buffer [10 mM Tris‑HCl (pH 8.3) and 50 mM 
KCl], 2.5 mM dNTPs (Promega Corporation, Madison, 
WI, USA), 5 pmols of each primer (IDT Integrated DNA 
Technologies, Coralville, IA, USA) and 1 unit of GoTaq® Flexi 
DNA polymerase (Promega Corporation). PCR conditions: 
94˚C for 7 min, followed by 33 cycles of 94˚C for 1 min, at the 
optimized annealing temperature for 1 min and 72˚C for 1 min 
and a final extension step of 72˚C for 10 min was performed 
in a thermocycler (Veriti Thermal Cycler; Thermo Fisher 
Scientific, Waltham, MA USA). The annealing temperature 
and MgCl2 concentration were optimized for each primer 
set. The primer nucleotide sequences, amplicon sizes and 
annealing temperatures are shown in Table I.
PCR products were purified using the Wizard® SV 
Gel and PCR Clean‑Up kit (Promega Corporation) and 
purified products were directly sequenced using the 
BigDye® Terminator v3.1 kit (Thermo Fisher Scientific) and 
an Applied Biosystems™ 3500Dx Genetic Analyzer (Thermo 
Fisher Scientific). Sequence variants detected were recon-
firmed by performing a second PCR and direct sequencing.
Sequencing results were analysed to identify variants 
by alignment with a human TP53 NCBI reference sequence 
(GenBank accession number‑NC_000017), via Bio Edit® soft-
ware and further confirmed by Mutation Surveyor® v4.0.9 and 
Alamut® Visual 2.7.2 Documentation. Identified sequence vari-
ants were named according to the Human Genome Variation 
Society/HGVS nomenclature guidelines (http://www.hgvs.
org/mutnomen/).
Variant analysis. Identified sequence variants were checked 
for previous reports in the following databases: Catalogue 
Of Somatic Mutations in Cancer (COSMIC) (http://cancer.
sanger.ac.uk/cosmic); NCBI (https://www.ncbi.nlm.nih.gov/); 
IARC TP53 (http://p53.iarc.fr/); Ensembl (https://asia.ensembl.
org/index.html); the p53 website (https://p53.fr/tp53‑database).
Pathogenicity of the identified exonic variants was anal-
ysed using five comparative missense prediction programs: 
Align GVGD (http://agvgd.hci.utah.edu/agvgd_input.
php); SIFT (http://sift.jcvi.org/www/SIFT_seq_submit2.
html); MutationTaster (http://www.mutationtaster.org/); 
PolyPhen‑2 (http://genetics.bwh.harvard.edu/pph2/); Provean 
(http://provean.jcvi.org/seq_submit.php). p53 specific struc-
tural and functional activity (transcriptional activity, dominant 
negative effect) data available on IARC TP53 database was 
also considered while determining the pathogenicity of the 
identified variants (18,19). Human Splicing Finder V3.0 
(http://www.umd.be/HSF3/) and splicing window of Alamut® 
Visual software, integrating a number of prediction methods 
(for splice signal detection: MaxEntScan, GeneSplicer 
and ESE/exonic splicing enhancer binding site detection: 
ESEFinder, RESCUE‑ESE) were used to assess the impact on 
gene splicing of identified intronic variants. All variants were 
classified according to American College of Medical Genetics 
standards and guidelines (20).
Immunohistochemistry for p53. IHC characterization of p53 
expression was performed on twenty four randomly selected 
representative formalin fixed paraffin‑embedded tumour tissue 
sections. The primary antibody used was mouse monoclonal 
Anti‑Human p53 clone DO‑7 (Agilent DaKo, Santa Clara, 
USA) at 1:100 dilution. Tissue sections of 4 micron thickness 
were mounted on microscopic slides and dried at 60˚C for 2 h. 
After dewaxing in xylene, sections were rehydrated in graded 
(100, 95, 70 and 60%) alcohol. Microwave heating in citrate 
(pH 6) buffer was used for antigen retrieval and endogenous 
peroxidase was inhibited by incubating tissue sections in 
freshly prepared 3% hydrogen peroxide. Tissue sections were 
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incubated with primary antibody at room temperature for an 
hour and then exposed to horseradish peroxidase (A. Menarini 
Diagnostics Ltd., Winnersh, UK) conjugated anti‑mouse IgG 
secondary antibody for 30 min. Universal probe (A. Menarini 
Diagnostics Ltd.) was applied for 30 min before the addi-
tion of primary antibody, in order to increase the staining 
sensitivity 10 to 40 times for mouse monoclonal antibodies. 
Then, the slides were incubated with 3,3'‑diaminobenzidine 
(A. Menarini Diagnostics Ltd.). Following the incubation, the 
sections were washed and counter stained with haematoxylin. 
Slides that were not incubated in primary antibody were 
used as antibody negative controls to check for specificity of 
staining.
Images of the stained slides were visualized using 
the AperioScanScope® CS System, an automated digital 
scanner (Aperio Technologies, Bristol, UK) technology and 
Spectrum™ image management software. The slides were 
analysed by both automated and manual methods, blinded 
from the clinical data.
Human papilloma virus DNA screening. PCR with 
GP5+/GP6+ HPV specific primers was performed for all HNC 
samples in a final volume of 25 µl containing 100‑150 ng 
genomic DNA, 3.5 mM MgCl2, 1X Green GoTaq
® reaction 
buffer [10 mM Tris‑HCl (pH 8.3) and 50 mM KCl], 2.5 mM 
dNTPs (Promega Corporation), 50 pmols of each primer (IDT 
Integrated DNA Technologies) and 1 unit of GoTaq® Flexi 
DNA polymerase (Promega Corporation). PCR conditions: 
94˚C for 4 min, followed by 40 cycles of 94˚C for 1 min, 40˚C 
for 1 min and 72˚C for 1 min and a final extension step at 72˚C 
for 10 min (21). The negative control included all reagents 
except for DNA. A p1203 PML2d HPV‑16 plasmid (gift from 
Peter Howley: Addgene plasmid #10869) was used as the posi-
tive control. Samples positive for HPV generate a 140‑bp‑long 
fragment from the HPV L1 structural gene.
p16 immunohistochemistry. p16 cyclin‑dependent kinase 
inhibitor protein expression was detected using IHC at the 
pathology laboratory of the Royal Victoria Infirmary, Newcastle 
upon Tyne using a Ventana Benchmark XT Automated 
IHC/In situ hybridization slide staining system (Ventana 
Medical Systems, Inc., Tucson, AZ, USA). The CINtec® p16 
Histology (Hoffmann‑La Roche AG, Basel, Switzerland) and 
UltraView DAB detection kit (Ventana Medical Systems Inc.) 
were used for the detection of p16. Images of the stained slides 
were visualized and analysed using the same process as for 
p53 detection.
Patient follow‑up. Data on response to treatment, survival, 
recurrence and current status during the follow‑up period were 
collected by reviewing patient medical records and collecting 
data directly from patients/guardians.
Statistical analysis. All categorical data were analysed using 
Fisher's exact test to assess the significance of the associations. 
A P‑value <0.05 was considered as statistically significant.
Results
Baseline characteristics of participants. Out of the 
44 patients, 75% (N=33) were males and 25% (N=11) were 
females. Mean ± SD age was 59.03±11.68 years for males 
and 53.27±19.04 years for females. Healthy controls were 
younger (males 33.2±4.92; females 33.1±5.84 years). Table II 
summarizes the characteristics of the patients, tumour type 
and possible risk factors the patients were exposed to.
Analysis of TP53 sequence variants and epidemiological/clin‑
ical correlations. A total of 36 sequence variants (18 translated 
exonic variants, 12 intronic and 2 non‑translated exonic vari-
ants) were found in 44 patients and 4 additional sequence 
variants were found only in healthy controls (two exonic silent 
and two novel intronic variants). Table III illustrates the char-
acteristics, In silico and functional analysis of each variant. 
All the exonic variants were in the DNA binding domain of the 
p53 protein (codons 94‑292).
c.298delC/p.Gln100Argfs*23, a novel heterozygous 
frameshift variant in exon 4 that created a stop codon at posi-
tion 123, was found in a male patient with upper oesophageal 
cancer (Fig. 1) diagnosed at 51 years of age. A c.383delC/p.
Pro128Leufs*42 frameshift variant in exon 5 that created a 
stop codon at position 170 was also found in a male patient 
with cancer recurrence in the vocal cord.
A novel 12 base pair in‑frame deletion in exon 6 
(c.626_637delGAA ACA CTT TTC/p.Asn210_Arg213del), that 
would results in the loss of 4 amino acid residues from 210 to 
213, producing a 389 amino acid protein (Fig. 2) was detected 
in the tumour DNA of a 61‑year‑old male patient with oesopha-
geal cancer.
Another male patient with recurrent cheek cancer had one 
nonsense pathogenic variant, c.493C>T (p.Gln165*) in exon 5, 
creating a stop codon at position 165, together with a patho-
genic missense variant (c.578A>G/p.His193Arg) in exon 6 
and survived only two years and eight months following 
recurrence. A c.637C>T (p.Arg213*) a nonsense pathogenic 
variant in exon 6, creating a stop codon at 213 position was 
Table I. Nucleotide sequence of primers used for amplification 
of TP53, amplicon size and annealing temperature.
  Amplicon Annealing
 Primer sequence,  size temperature
Exon 5'‑3' (bp) (˚C)
2 and 3 CAGCCATTCTTTTCCTGCTC 497 62
 GGGGACTGTAGATGGGTGAA
4 CCTGGTCCTCTGACTGCTCT 361 64
 GCCAGGCATTGAAGTCTCAT
5 and 6 GTTTCTTTGCTGCCGTCTTC 500 64
 CTTAACCCCTCCTCCCAGAG
7 GAGCTTGCAGTGAGCTGAGA 444 63
 TCCCAAAGCCAGAGAAAAGA
8 and 9 CAAGGGTGGTTGGGAGTAGA 532 65
 TGTCTTTGAGGCATCACTGC
10 TGCATGTTGCTTTTGTACCG 299 56
 GAAGGCAGGATGAGAATGGA
11 TGTCATCTCTCCTCCCTGCT 438 61
 AAGTGGGCCCCTACCTAGAA
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observed in a 72‑year‑old male patient with tumour of the 
mandible.
A 59‑year‑old female patient with a malignancy in the 
cheek carried two variants in exon 5; a pathogenic missense 
variant (c.422G>T/p.Cys141Phe) and a likely‑pathogenic 
missense variant (c.467G>A/p.Arg156His). She survived for 
one year and eight months following diagnosis.
Another 59‑year‑old male patient had a cancer diagnosed in 
2010 in the retro molar region which recurred in the mandible 
after 5 years. He had a single pathogenic missense variant, 
c.455C>T/p.Pro152Leu in exon 5. Another pathogenic variant, 
c.524G>A/p.Arg175His in exon 5 was observed in a male 
patient with left antral malignancy and in a female patient with 
oesophageal cancer.
Table II. Baseline characteristics of the patients, tumour type and possible risk factors the patients were exposed to.
     Two‑tailed P‑value
 Total number Patients with Patients with Total number between patient
Characteristics of patients wild‑type TP53, no. mutated TP53, no. of healthy controls and healthy controlsa
Sex
  Male 33 23 10 10 0.1176
  Female 11 7 4 10
Ethnicity
  Sinhalese 35 23 12 13 0.0888
  Sri Lankan Tamil 3 3 0   5
  Indian Tamil 3 1  2   1
  Muslims 3 3  0    0
  Burghers 0 0  0    1
Age at study entry
  <30 years 2 2  0    2 0.0007
  30‑60 years 24 14 10 18
  >61 years 18 14 4   0
Tumour type
  Squamous cell carcinoma 25 13 12 N/A N/A
  Adenocarcinoma 4 3  1  N/A
  Papillary carcinoma 4 4 0  N/A
  Others 11 10  1  N/A
Smoking history
  Yes 17 11 6   0 0.0005
  No 25 17 8 20
  Unknown 2 2  0    0
Alcohol consumption
  Yes 13 8 5   1 0.0251
  No 29 20 9 19
  Unknown 2 2  0    0
Betel‑quid chewing
  Yes with tobacco 21 12  9    0 <0.0001
  Yes without tobacco 2 2 0   0
  No 19 14 5 20
  Unknown 2 2  0    0
Roofing
  Asbestos 21 14  7    1 <0.0001
  Tile 15 11 4   5
  Concrete 1 1  0 12
  Metal 3 2  1    0
  Unknown 4 2  2    2
Codon 72 polymorphism     0.6225
  Arginine 10 6 4   7
  Proline 19 12 7   7
  Arginine/proline 15 12 3   6
aFisher's exact test was done to examine the significance of the associations between patients and healthy controls. A P‑value <0.05 was considered as 
statistically significant.
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Four pathogenic missense variants were detected in exon 6 
(c.583A>T, c.659A>G, c.646G>C, c.578A>G). One male 
patient aged 59 diagnosed with upper oesophageal cancer had 
a c.583A>T/p.Ile195Phe variant. A c.659A>G/p.Tyr220Cys 
variant was found in a 55‑year‑old male patient with malignancy 
in the retro molar region. This variant co‑existed with another 
pathogenic variant, c.818G>A/p.Arg273His, in exon 8. 
Co‑existence of c.646G>C and c.648G>C (p.Val216Leu) 
variants were identified in the malignant cheek tumour of a 
60‑year‑old female patient.
Figure 1. Novel frameshift variant c.298delC/p.Gln100Argfs*23 detected in Exon 4. (A) Mutation Surveyor®V4.0.9 image indicating the one base pair hetero-
zygous deletion point; R indicates the reference TP53 sequence and S indicates the study sample TP53 sequence. (B) p53 immunohistochemical staining of the 
tumour sample with the above mutation. Magnification, x20. (C) Protein prediction using Mutalyzer 2.0.26.
Figure 2. Novel in‑frame deletion c.626_637delGAAACACTTTTC/p.Asn210_Arg213del detected in exon 6. (A) Mutation Surveyor®V4.0.9 image indicating 
the 12‑base pair heterozygous deletion; R indicates the reference TP53 sequence and S indicates the study sample TP53 sequence. (B) Protein prediction using 
Mutalyzer 2.0.26.
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c.576G>C/p.Gln192His, a likely‑benign variant was identi-
fied in exon 6 in a 68‑year‑old female patient with oesophageal 
cancer and in a male patient with arytenoid cartilage cancer. 
The only pathogenic missense variant c.747G>T/p.Arg249Ser 
in exon 7 was observed in a male patient aged 68 years with 
cancer in the cheek.
A c.844C>T/p.Arg282Trp variant in exon 8 was found 
in a 60‑year‑old female patient with a mandible cancer who 
survived only 1 year and 5 months following diagnosis.
Among the 14 patients who had pathogenic variants, eight 
had a history of betel quid‑tobacco chewing, five in the absence 
of smoking or alcoholism and three in the presence of smoking 
and alcoholism. Six of the patients with pathogenic variants 
did not have a history of betel quid‑tobacco chewing, but three 
of them were smokers and had a history of alcoholism.
Among the intronic variants, c.994‑95delT, a novel dele-
tion in intron 9 was identified in 4 patients but not in controls 
and c.97‑29C>A, a reported variant substitution in intron 3, 
which was identified in four patients and in two controls were 
categorized as variants with uncertain significance as both 
alter the WT branch point and potentially alter the splicing 
according to Human Splicing finder.
Two novel variants were found in the 5'UTR of the 
gene; c.‑140G>A (N=4) and c.‑159delT (N=1) in patients 
but not in healthy controls. Three more novel intronic 
variants were found in patients [c.74+16G>C (N=2), 
c.375+37C>A (N=1), c.1100+76T>A (N=2)] in introns 2, 
4 and 10 respectively but not in any healthy controls. In 
contrast, two other novel variants [c.75‑42G>A (intron 2) and 
c.782+79C>T (intron 7)] were observed in healthy controls but 
not in patients.
TP53 gene status and expression of p53 protein. Twenty four 
samples were randomly chosen for IHC analysis. The H‑Score 
for each slide was calculated by multiplying the intensity of 
staining (no staining, 0; weak, 1; intermediate, 2; and strong, 3) 
by the percentage of cells at each staining intensity level. 
Scores ranged from 0 to 300. Scores were grouped into three 
categories; from 0 to <1 was considered negative (Pattern‑C), 
score ranging from 1 to 20 (Pattern‑B) and all the scores >20 
(Pattern‑A) (Fig. 3).
IHC staining for p53 showed positive immuno‑reactivity 
in 13/24 (54.17%) cases. Nine of these tumours showed wide-
spread IHC positive tumour nuclear staining involving either 
the entire tissue section or a segment of it (Pattern‑A) while 
4 showed rare/scattered p53 positive single tumour nuclei 
(Pattern‑B). All cases with a missense variant in TP53 gene 
showed Pattern‑A IHC staining. However, vice versa is not 
true because 2 cases showed IHC positivity with Pattern‑A 
in the absence of detectable pathogenic TP53 gene variants. 
These had only ~10% of positively stained tumour cells in the 
respective tissue sections. One case with both missense and 
nonsense variants showed Pattern‑A IHC staining. All 4 cases 
with Pattern‑B IHC staining had no detectable pathogenic 
TP53 variants. Among the 11 cases with immuno‑negativity 
(Pattern‑C), two had frameshift variants and one had a 
nonsense variant. The remaining eight patients who showed 
immuno‑negativity had wild‑type TP53.
Prevalence of HPV. Sensitivity of the GP5+/GP6+ primer pair 
was at the level of femtograms for HPV genotypes which 
match strongly with the primers and at the level of picograms 
for HPV genotypes having four or more mismatches to the 
primers (21). Absence of positive results in our study cohort 
indicated either absence of HPV DNA or the presence of HPV 
DNA at a concentration below the level of sensitivity.
The IHC staining for p16 is defined as positive if there is 
strong and diffuse nuclear and cytoplasmic staining pattern 
in >70% of the tumour specimen (Fig. 4). Regardless of cancer 
type, TP53 mutation status and p53 protein expression, all 
HNC samples in the Sri Lankan study cohort were negative 
for p16 staining, despite clear positive staining with the control 
sample.
Discussion
This is a preliminary study on Sri Lankan HNC patients, 
focused on the mutation spectrum of the TP53 gene, expres-
sion of p53 protein and relationship to possible risk factors. In 
the present study, we also included upper oesophageal cancer, 
as HNCs are often associated with oesophageal cancer and 
both tumour types share common risk factors (22).
Identification of hotspot regions of TP53 mutations in the 
Sri Lankan context is useful to prioritize screening of such 
regions rather screening the entire gene, prior to treatment. In 
the current study, 70% (11 out of 15) of pathogenic mutations 
reported were detected in the exon 5 and 6 which is covered 
by a single set of primer. Therefore it is worth to understand 
the hotspot region in TP53 for initiation of screening of TP53 
in a resource limited setting such as Sri Lanka. Hotspot 
Figure 3. IHC characterization of p53 detected by DO7 antibody. (A) Pattern A with wide spread IHC positive nuclei‑IHC score >20. (B) Pattern B with rare 
positive single tumour nuclei‑IHC score from ≥1 to ≤20; arrows indicate the rare positive cells. (C) Pattern C with no IHC positive nuclei‑IHC score from 
0 to <1. Magnification, x20. IHC, immunohistochemistry.
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regions of TP53 identified in the present study are similar to 
those reported for other ethnic groups. This is also supported 
by the data in the ‘IARC TP53 database’ (http://p53.iarc.
fr/TP53SomaticMutations.aspx) and ‘cBioPortal for cancer 
genomics’ (http://www.cbioportal.org/).
A mong t he  pa t hogen ic  va r ia nt s  found,  t he 
frameshift variant c.298delC and in‑frame variant 
c.626_637delGAAACACTTTTC have not been previously 
reported. The c.646G>C somatic missense variant is reported 
only in the IARC TP53 database, but the details are not 
provided. c.383delC and c.576G>C are novel variants in HNCs, 
as they have been reported only in the COSMIC database for 
breast and stomach tumours respectively. Although c.422G>T, 
c.455C>T, c.467G>A, c.747G>T and c.818G>A have been 
commonly reported for many types of cancer, these variants 
have not been reported in HNC or oesophageal cancer.
 Some mutations of TP53 such as frame shift deletions or 
insertions and nonsense or splice site mutations are recessive 
and require loss of the remaining normal allele for cells to lose 
p53 tumour suppressor function. However, some point missense 
mutant forms can have a dominant‑negative effect (DNE) 
because they are no longer recognised by their negative regu-
lator MDM2 and accumulate in the cell to a much greater 
level than the normal wild‑type TP53 allele. These so-called 
‘dominant‑negative’ forms of mutant p53 nevertheless have lost 
their normal transcriptional activity. Loss of function of each 
identified variant in the current study was assessed based on 
the reported loss of transcriptional activity data available in 
the IARC and other databases. Overall transcriptional activity 
of 2314 distinct mutant proteins has been experimentally 
measured on a panel of p53‑response elements of promoters 
of downstream transcriptional target genes such as CDKN1A 
(p21), MDM2 and BAX (23‑25). In addition sequence variants 
have also been evaluated using a computational geometry 
approach called Delaunay Tessellations to predict the func-
tional impact (26). DNE of sequence variants has been assessed 
based on studies carried out on promoters of p21WAF, Ribosomal 
Gene Clusters, etc. (24). Out of ten pathogenic missense vari-
ants reported in our study cohort, nine (c.455C>T, c.524G>A, 
c.578A>G, c.583A>T, c.659A>G, c.646G>C, c.747G>T, 
c.818G>A and c.844C>T) are predicted to involve complete 
loss of transcriptional function based on databases compiled 
from both yeast assay and computational method.
Codon 72 variant (p.Arg72Pro) in exon 4 is a well‑known 
polymorphism present in the normal human population. The 
implication of this polymorphism in cancer risk and prognosis 
is controversial, with some earlier studies reporting that p53 
protein containing the codon 72 Arginine form has a greater 
apoptotic potential (27‑31) while others have failed to repli-
cate these findings (32,33). In the present study neither the 
p.Arg72Pro alleles was significantly associated with cancer.
One previous study of TP53 carried out in 1998 on 23 oral 
squamous cell carcinoma from Sri Lankan patients has been 
published. This reported nine sequence variants: Missense 
variant in codons 135, 164, 176, 245, 248; deletions in codons 
130, 144‑148, 172‑187 and one insertion in codon 250 (34). 
None of these variants were found in the current study, which 
included 19 patients with oral squamous cell carcinoma. 
However studies done in all subset of HNC in India and Japan 
showed 21 and 11.6% of pathogenic TP53 variant and 69 and 
13.7% of HPV positivity respectively (16,17).
Generally, for head and neck cancers without HPV infection 
has a higher prevalence of TP53 mutation. However, the lower 
percentage of TP53 mutations was observed in the current study 
is due to the inclusion of thyroid cancer in the studied cohort 
as it is considered under head and neck cancer in Sri Lankan 
context. In the current study, out of 44 patients, 9 patients were 
with thyroid carcinoma and none of them carried any patho-
genic TP53 variants, which may be the possible reason for a 
decreased percentage of TP53 mutation prevalence (35,36).
TP53 mutations can be classified as disruptive and 
non‑disruptive based on the location and type of muta-
tions. Disruptive mutations are missense mutations located 
in the DNA‑binding domain, or stop codons in any region 
which create truncated proteins. Non‑disruptive mutations 
are missense mutations located outside the DNA binding 
domain. Disruptive mutations are closely associated with poor 
prognosis of head and neck cancer (37) and all the reported 
pathogenic somatic TP53 mutations in the current study are 
associated with poor prognosis.
However, we also analysed the pathogenic missense muta-
tions with a computational approach called evolutionary action 
or EAp53, which has been validated both in vivo and in vitro, 
for TP53 mutation classification (http://mammoth.bcm.tmc.
edu/EAp53/). This approach assigns an evolutionary action 
score and classifies each p53 missense mutation as either high‑ 
or low‑risk. According to Neskey et al (38), patients with high 
risk TP53 mutations show poor survival with high invasive and 
aggressive tumour behaviour. According to the EAp53 analysis 
c.422G>T, c.455C>T, c.524G>A, c.578A>G, c.747G>T were 
Figure 4. Detection of p16 expression using Ventana Benchmark XT Automated immunohistochemistry/in situ hybridization slide staining system. (A) Positive 
control showing positive staining of nuclei and cytoplasm. (B) A study sample with negative staining. Magnification, x20.
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categorized as high risk mutations and c.583A>T, c.646G>C, 
c.659A>G, c.818G>A, c.844C>T as low risk mutations. In 
addition all truncating mutations are also considered to have 
poor prognosis.
Generally wild‑type p53 protein has very short half‑life in 
the cells under normal conditions due to constant degradation 
by the MDM2‑mediated negative feedback loop (39). In the 
case of mutant p53 protein, MDM2 protein cannot be induced, 
thus MDM2‑mediated negative feedback is absent leading 
to accumulation of mutant p53 (40). It is also reported that a 
contribution to the stabilization of mutant p53 is due to impaired 
ubiquitination (41). All the missense variations identified in 
the current study showed the accumulation of p53 protein with 
the Pattern‑A strong immunostaining. However the converse 
was not true, as there were two samples with Pattern‑A IHC 
which showed no detectable variations in sequence. But these 
two samples have only <10% of tumour cells in the sections 
used for immunostaining which would have been below the 
sensitivity of detection by sanger sequencing.
All the truncated proteins that resulted either from frame-
shift or nonsense variations showed immuno‑negativity. The 
antibody used to detect the expression of p53 protein is DO‑7 
which binds to the p53 protein between amino acid 1‑45 (42). 
Even though all four truncated protein are longer than 123 
amino acids, they remained undetectable. This may be due 
to nonsense‑mediated decay of mRNA with premature stop 
codon may have resulted in less stable truncated proteins.
All the samples (N=4) with Pattern‑B IHC were TP53 
wild‑type and, there were 57% (8/14) of the wild‑type samples 
that showed no positive immuno‑reactivity. Thus IHC analysis 
cannot be used as a standalone method to detect the alteration 
in p53 as it cannot differentiate between truncated p53 protein 
and wild‑type p53 protein as both show an immuno‑negative 
IHC pattern.
Cigarette smoking and alcoholism are well known triggers 
of HNCs. The awareness of these risk factors is higher among 
Sri Lankans. But despite a reduction in cigarette smoking, the 
burden of HNC has increased constantly over the years, which 
prompted us to search for other risk factors.
Betel‑quid chewing with tobacco is a common habit among 
Sri Lankans especially those who are engaged in hard physical 
work for long hour. Furthermore, there is poor awareness of 
the harmfulness of this habit. 47.7% of the patients (N=21) 
studied were addicted to betel‑quid chewing with tobacco and 
out of them, nine have TP53 sequence variants conferring an 
altered protein structure.
HPVs are non‑enveloped DNA viruses, containing a 
double stranded circular DNA which consists of an upstream 
regulatory region (URR), an early region (E) encoding viral 
regulatory proteins and a late region (L) encoding viral 
capsid proteins (43). HPV is an identified cause of HNCs and 
it is reported that HPV‑positive HNCs have a better prog-
nosis (44‑46). The high‑risk HPV proteins E6, E7 target tumour 
suppressor proteins p53 and RB respectively. Disruption of the 
function of p53 and pRB lead to uncontrolled cell division (47). 
Here we studied the expression of p16 protein which is used 
as a surrogate marker to identify functionally active HPV 
infection as it is reciprocally overexpressed due to functional 
inactivation of pRB by E7 protein (48,49). Several previous 
studies in other countries reported p16 overexpression in HNC. 
The highest (38%) and lowest (7.8%) level of p16 expression 
are reported in the USA, while intermediate levels are reported 
from India (20%) and Kenya (14.6%) (50‑53). All samples in 
our study cohort were negative for p16 staining which may 
suggest the absence of functionally active HPV infection (54).
In a previous study from Sri Lanka 37.2% of tumour 
samples from oral cancer patients were reported to be infected 
when analysed using HPV DNA typing (18). However in the 
current study, none of the patients were positive on DNA 
typing which also indicates the absence or presence of very 
low concentration of HPV DNA in the tumour samples.
It has also been reported that p53 protein with the 
Arginine72 polymorphism is efficiently degraded by the 
E6 protein of HPV 16, thus increasing susceptibility to 
cancer (55). Nevertheless, there are studies that show no 
correlation between p.Arg72Pro and HPV related cervical 
cancers (56,57). Our cohort of HNC patients also showed no 
correlation between p.Arg72Pro and HPV infection.
Exposure to asbestos due to living in houses with asbestos 
roofing and exposure to rubber by occupations may also have 
contributed to mutagenesis of TP53 and carcinogenesis in 
some patients in the present cohort.
In conclusion, we examined all exons and splicing sites of 
the TP53 gene in HNC and oesophageal cancers from a cohort 
of Sri Lankan patients and found a high occurrence of gene 
alterations including several novel variants. All p53 protein 
altering variants found were positioned between exons 4‑8. 
Only the point missense variants were associated with strong 
immuno‑positivity, thus limiting the use of IHC in detecting 
mutation status of p53. Our cohort of patients did not appear to 
carry significant levels of HPV infection.
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